Published in Arterioscler Thromb Vasc Biol on May 01, 2008
Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol (2010) 2.17
Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab (2008) 1.79
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Adiponectin and cardiovascular health: an update. Br J Pharmacol (2012) 1.42
Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol (2011) 1.41
Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol (2010) 1.34
Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr (2010) 1.20
A novel role for adiponectin in the regulation of inflammation. Arterioscler Thromb Vasc Biol (2008) 1.18
Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement (2009) 1.08
CRP and the risk of atherosclerotic events. Semin Immunopathol (2009) 1.06
Adiponectin in inflammatory and immune-mediated diseases. Cytokine (2013) 1.05
Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol (2010) 0.99
Decrease of miR-146b-5p in monocytes during obesity is associated with loss of the anti-inflammatory but not insulin signaling action of adiponectin. PLoS One (2012) 0.94
Nitric oxide-induced activation of the AMP-activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in endothelial cells. PLoS One (2011) 0.93
Protective effects of AMP-activated protein kinase in the cardiovascular system. J Cell Mol Med (2010) 0.91
Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years. Diabetologia (2011) 0.91
Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag (2015) 0.87
Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat Commun (2015) 0.86
Activation of AMP-activated protein kinase prevents lipotoxicity in retinal pericytes. Invest Ophthalmol Vis Sci (2011) 0.86
Molecular sex differences in human serum. PLoS One (2012) 0.83
2-(2,4-dihydroxyphenyl)-5-(E)-propenylbenzofuran promotes endothelial nitric oxide synthase activity in human endothelial cells. Biochem Pharmacol (2012) 0.83
NF-kappaB-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin. Endocrinology (2011) 0.82
Cardiac Fibrosis Alleviated by Exercise Training Is AMPK-Dependent. PLoS One (2015) 0.81
Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome. Diabetol Metab Syndr (2014) 0.78
Influence of smoking and body weight on adipokines in middle aged women. Eur J Med Res (2009) 0.76
Serum Adiponectin and Indices of Cardiovascular Risk in Young Women with Excessive Body Mass. EJIFCC (2010) 0.75
Retinol-binding protein 7 is an endothelium-specific PPARγ cofactor mediating an antioxidant response through adiponectin. JCI Insight (2017) 0.75
C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation. Int Sch Res Notices (2014) 0.75
AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs. PLoS One (2015) 0.75
Insulin-like growth factor-I and insulin-like growth factor binding protein-1 are related to cardiovascular disease biomarkers in obese adolescents. Pediatr Diabetes (2014) 0.75
The evolving role of adiponectin as an additive biomarker in HFrEF. Heart Fail Rev (2016) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med (2001) 16.51
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 14.15
ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab (2002) 4.64
Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A (2002) 4.40
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem (2002) 4.16
Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem (2003) 3.86
Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation (2003) 3.73
Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med (2005) 3.29
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov (2004) 2.46
Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med (2004) 2.39
Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res (2005) 2.28
Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes (2003) 2.11
Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes (2007) 2.08
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J (1989) 1.98
Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun (2004) 1.92
High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab (2007) 1.85
Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol (1991) 1.60
Intracellular pH during "chemical hypoxia" in cultured rat hepatocytes. Protection by intracellular acidosis against the onset of cell death. J Clin Invest (1989) 1.53
Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol (2003) 1.48
Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res (2000) 1.43
Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl (2005) 1.37
AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Med Sci Sports Exerc (2004) 1.29
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int (2005) 1.27
Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia (2003) 1.26
Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol (2006) 1.23
C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol (2006) 1.21
C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia (2007) 1.18
Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol (2007) 1.14
Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun (2005) 1.14
CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol (2008) 1.10
Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord (2003) 1.10
Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol (2005) 1.10
Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res (2002) 1.08
Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract (2005) 0.99
Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun (2005) 0.99
The interaction of C-Rel with C/EBPbeta enhances C/EBPbeta binding to the C-reactive protein gene promoter. Mol Immunol (2007) 0.96
C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol (2007) 0.94
Relationship of adiponectin with insulin sensitivity in humans, independent of lipid availability. Obesity (Silver Spring) (2006) 0.88
C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med (2003) 0.84
C-reactive Protein. J Biol Chem (2004) 4.39
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab (2007) 2.84
Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr (2005) 2.72
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes (2006) 2.65
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 2.50
Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care (2010) 2.39
High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes (2008) 2.23
What does minor elevation of C-reactive protein signify? Am J Med (2006) 2.14
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 2.09
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res (2005) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine (2011) 1.91
Retracted Alpha-lipoic acid supplementation and diabetes. Nutr Rev (2008) 1.86
High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab (2007) 1.85
Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes (2007) 1.84
C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res (2007) 1.82
De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl (2007) 1.68
Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol (2012) 1.67
Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol (2005) 1.66
Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem (2005) 1.53
Oxidative stress and atherosclerosis. Pathophysiology (2006) 1.52
Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am J Clin Nutr (2005) 1.51
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol (2008) 1.51
Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes (2005) 1.50
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab (2010) 1.45
Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. Arterioscler Thromb Vasc Biol (2004) 1.43
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.42
Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol (2009) 1.40
Quantification of daratumumab in the serum protein electrophoresis. Clin Chem Lab Med (2016) 1.39
CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol (2010) 1.37
Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol (2011) 1.34
C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation (2003) 1.34
Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology (2003) 1.33
Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol (2006) 1.32
Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med (2007) 1.30
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
Adipose tissue dysfunction in nascent metabolic syndrome. J Obes (2013) 1.26
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis (2009) 1.26
Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab (2011) 1.25
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes (2002) 1.24
Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol (2005) 1.23
Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults. Am J Clin Nutr (2002) 1.23
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol (2006) 1.21
Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab (2003) 1.19
C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation (2007) 1.19
SREBP-1c and Sp1 interact to regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver. J Biol Chem (2004) 1.18
Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am (2004) 1.17
Innate immunity genes influence the severity of acute appendicitis. Ann Surg (2004) 1.16
C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol (2011) 1.15
A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol (2002) 1.14
Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr (2007) 1.14
Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens (2005) 1.14
Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4alpha. J Biol Chem (2009) 1.12
CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol (2008) 1.10
Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol (2005) 1.10
Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol (2013) 1.10
Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter. Mol Immunol (2003) 1.09
Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab (2010) 1.06
CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol (2006) 1.04
Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg (2003) 1.03
The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly. Ann Surg (2006) 1.02
Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism (2010) 1.02
Failure of vitamin E in clinical trials: is gamma-tocopherol the answer? Nutr Rev (2005) 1.01
Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab (2005) 1.01
Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol (2011) 1.01
Role of TNF-alpha in gut mucosal changes after severe burn. Am J Physiol Gastrointest Liver Physiol (2002) 1.00
C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol (2005) 1.00
High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome. Metabolism (2008) 1.00
Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. J Nutr (2002) 0.99
A unifying biologic explanation for "high-sensitivity" C-reactive protein and "low-grade" inflammation. Arthritis Care Res (Hoboken) (2010) 0.99
Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord (2008) 0.98
Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol (2007) 0.98
Coenzyme Q10 supplementation and heart failure. Nutr Rev (2007) 0.98
Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr (2006) 0.98
Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem (2010) 0.97
Anti-inflammatory effects of alpha-tocopherol. Ann N Y Acad Sci (2004) 0.97
Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol (2004) 0.97
The interaction of C-Rel with C/EBPbeta enhances C/EBPbeta binding to the C-reactive protein gene promoter. Mol Immunol (2007) 0.96
Statins and biomarkers of inflammation. Curr Atheroscler Rep (2007) 0.96
TLR2 expression and signaling-dependent inflammation impair wound healing in diabetic mice. Lab Invest (2010) 0.96
Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism (2004) 0.96
Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol (2012) 0.95
Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem (2011) 0.95
C-reactive protein and systemic lupus erythematosus. Arthritis Rheum (2008) 0.94
C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem (2008) 0.94
Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis (2006) 0.94
Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol (2008) 0.93
Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med (2004) 0.93
Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis (2008) 0.93
C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem (2011) 0.93
Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology (2009) 0.93
Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol (2009) 0.92